Directorate Change
Source: RNS
18 October 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Directorate change
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that, further to the announcement made on 12 September 2024 in which it stated that Dr Matthew Stork had stepped down as Chief Executive Officer, the Company has now received the formal resignation of Dr Stork as a Director of the Company and all subsidiary entities of which he was a Director.
Enquiries:
|
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit: https://cambridgecognition.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
